- Public Comps
- Tempus AI
Tempus AI Valuation Multiples
Discover Tempus AI's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like ICON plc, UiPath, iFlytek, Revvity and more.
Tempus AI Overview
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Founded
2015
HQ

Employees
3.8K
Website
Sectors
Financials (LTM)
EV
$12B
Valuation Multiples
Start free trialTempus AI Financials
Tempus AI reported last 12-month revenue of $1.5B and EBITDA of $40M.
In the same LTM period, Tempus AI generated $960M in gross profit, $40M in EBITDA, and had net loss of ($252M).
Revenue (LTM)
Tempus AI P&L
In the most recent fiscal year, Tempus AI reported revenue of $1.3B and EBITDA of ($131M).
Tempus AI is unprofitable as of last fiscal year, with gross margin of 63%, EBITDA margin of (10%), and net margin of (19%).
Financial data powered by Morningstar, Inc.
Tempus AI Stock Performance
Tempus AI has current market cap of $12B, and enterprise value of $12B.
Market Cap Evolution
Tempus AI's stock price is $64.04.
Tempus AI share price increased by 46.0% in the last 30 days, and decreased by 15.6% in the last year.
Tempus AI has an EPS (earnings per share) of $-1.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12B | $12B | 0.0% | 46.0% | 26.9% | -15.6% | $-1.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTempus AI Valuation Multiples
Tempus AI trades at 8.2x EV/Revenue multiple, and 301.9x EV/EBITDA.
EV / Revenue (LTM)
Tempus AI Financial Valuation Multiples
As of August 31, 2026, Tempus AI has market cap of $12B and EV of $12B.
Tempus AI has a P/E ratio of (45.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tempus AI Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Tempus AI Margins & Growth Rates
Tempus AI grew revenue by 26% but EBITDA decreased by 149% in the last fiscal year.
In the most recent fiscal year, Tempus AI reported gross margin of 63%, EBITDA margin of (10%), and net margin of (19%).
Tempus AI Margins
Tempus AI Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Tempus AI Operational KPIs
Tempus AI's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Tempus AI's Rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tempus AI's Rule of X is 68% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Tempus AI Competitors
Tempus AI competitors include ICON plc, UiPath, iFlytek, Revvity, Range Intelligent, SenseTime Group, Solventum, Caris Life Sciences, Hinge Health and Presight AI.
Most Tempus AI public comparables operate across Health Data & Analytics, Vertical AI Applications, Artificial Intelligence, B2B SaaS, Horizontal SaaS, DeepTech, HealthTech and Generative AI.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.9x | 1.9x | 19.2x | 11.2x | |||
| 5.1x | 4.8x | 117.6x | 19.3x | |||
| 3.8x | 3.5x | 33.1x | 38.2x | |||
| 5.8x | 5.9x | 22.7x | 18.8x | |||
| 21.0x | 16.5x | 16.1x | 21.1x | |||
| 8.8x | 7.5x | (94.0x) | 362.5x | |||
| 2.4x | 2.5x | 8.0x | 9.3x | |||
| 8.5x | 7.2x | (1349.0x) | 41.1x | |||
This data is available for Pro users. Sign up to see all Tempus AI competitors and their valuation data. Start Free Trial | ||||||
Tempus AI VC Funding History
Before going public, Tempus AI raised $910M in total equity funding, across 10 rounds.
Last private valuation of Tempus AI was $10B, after raising $100M in October 2022.
Tempus AI Funding Rounds
Acquisitions by Tempus AI
Tempus AI has acquired 9 companies to date.
Last acquisition by Tempus AI was on July 19th 2026. Tempus AI acquired Personalis for $1.7B (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Tempus AI
| Description | Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. | Paige develops AI-powered computational pathology platforms originating from Memorial Sloan Kettering Cancer Center, launched in 2017 and New York-headquartered. The technology received FDA breakthrough device designation for its prostate cancer diagnostic tool, analyzing whole-slide images to enhance pathologist accuracy and workflow efficiency. Paige processes biopsies for hospitals worldwide, integrating with lab information systems. | Deep 6 AI is a Pasadena-headquartered software platform applying artificial intelligence to accelerate clinical trial recruitment. The technology parses electronic health records, including ICD-10 codes, physician notes, pathology reports, and surgical documentation, to match patients with trials. Founded in 2016, it partners with health systems to expedite site feasibility and enrollment. | Ambry Genetics is an Irvine, California-based privately held healthcare company offering the industry's broadest genetic testing portfolio. Its solutions reach insurers covering 90 percent of U.S. patients through public and private plans. Committed to open scientific collaboration, Ambry operates a CLIA- and CAP-accredited laboratory focused on hereditary cancer, cardiology, neurology, and reproductive health testing. | |
| HQ Country | |||||
| HQ City | San Francisco, CA | New York City, NY | Los Angeles, CA | Los Angeles, CA | |
| Deal Date | 19 Jul 2026 | 22 Aug 2025 | 7 Mar 2025 | 6 Nov 2024 | |
| Valuation | $1.7B | $81M | $17M | $600M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Tempus AI acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tempus AI
| When was Tempus AI founded? | Tempus AI was founded in 2015. |
| Where is Tempus AI headquartered? | Tempus AI is headquartered in United States. |
| How many employees does Tempus AI have? | As of today, Tempus AI has over 3K employees. |
| Who is the CEO of Tempus AI? | Tempus AI's CEO is Eric P. Lefkofsky. |
| Is Tempus AI publicly listed? | Yes, Tempus AI is a public company listed on Nasdaq. |
| What is the stock symbol of Tempus AI? | Tempus AI trades under TEM ticker. |
| When did Tempus AI go public? | Tempus AI went public in 2024. |
| Who are competitors of Tempus AI? | Tempus AI main competitors include ICON plc, UiPath, iFlytek, Revvity, Range Intelligent, SenseTime Group, Solventum, Caris Life Sciences, Hinge Health, Presight AI. |
| What is the current market cap of Tempus AI? | Tempus AI's current market cap is $12B. |
| What is the current revenue of Tempus AI? | Tempus AI's last 12 months revenue is $1.5B. |
| What is the current revenue growth of Tempus AI? | Tempus AI revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Tempus AI? | Current revenue multiple of Tempus AI is 8.2x. |
| What is the current EBITDA of Tempus AI? | Tempus AI's last 12 months EBITDA is $40M. |
| What is Tempus AI's EBITDA margin? | Tempus AI's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Tempus AI? | Current EBITDA multiple of Tempus AI is 301.9x. |
| What is the current FCF of Tempus AI? | Tempus AI's last 12 months FCF is $12M. |
| What is Tempus AI's FCF margin? | Tempus AI's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Tempus AI? | Current FCF multiple of Tempus AI is 1028.2x. |
| How many companies Tempus AI has acquired to date? | As of August 2026, Tempus AI has acquired 9 companies. |
| What was the largest acquisition by Tempus AI? | $1.7B acquisition of Personalis on 19th July 2026 was the largest M&A Tempus AI has done to date. |
| What companies Tempus AI acquired? | Tempus AI acquired Personalis, Ambry Genetics, Paige, Deep 6 AI, AKESOgen, Highline Sciences, Mpirik, Dawson Forte Cashmere, and Arterys. |
| In how many companies Tempus AI has invested to date? | Tempus AI hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Tempus AI
Lists including Tempus AI
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





